Clinical Trial Detail

NCT ID NCT02841748
Title A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago

head and neck cancer



Age Groups: adult senior

No variant requirements are available.